←
Tracy King466 posts
Tracy King avatar

Tracy King

@MMKingT

Haem Nurse - MM focus - passionate about real world optimal drug access / outcomes for all

◷ Joined August 2022▧ 135 Photos and videos
Tracy King avatar
Tracy King@MMKingT·Nov 7

Agree - now we have a psychometrically sound too SSQ-MM lets start to use it in studies or clinic, to reduce the adverse impact of dex on patients/carers. We know ☝️dex = 👇QOL

Another chapter in #downwithdex ! Great work by @MMKingT #fridaaskeland et al on translating the SSQ-MM steroid-related PRO inventory into another language. Turns out, regardless of what language you speak, dex-related AEs in myeloma are universal!

Tracy King avatar
Tracy King@MMKingT·Sep 27

Glasgow @profBigG delivered. Congratulations all #IMS26 @Myeloma_Society Excited to 👀all next yr at 🐘🇮🇳 Nursing & Allied Health welcome colleagues to contribute and be part of ongoing improved pt outcomes @mmamynurse @marymyeloma @Bethfaiman @domenica76 @RahulBanerjeeMD

Post attachment

Thank you to everyone who joined #IMS26, both in person and virtually. Save the date for next year’s meeting, taking place September 29–October 2 in New Delhi, India. We look forward to seeing you in 2027!

Post attachment
Tracy King avatar
Tracy King@MMKingT·Sep 26

Thats a wrap #IMS26 PERSEUS up front SOC- BsAB come forward-fixed duration therapies-looking forward to cure-InVivoCART ahead.

Post attachmentPost attachmentPost attachment
Tracy King avatar
Tracy King@MMKingT·Sep 25

Impressive - yet Dara not universally available 🌎🌍- take NZ as example - no access to Dara in any line!! #MMsM must continue to work towards IMPROVING access so all people can benefit from increased LIFE @MyelomaNZ @LBCNZ

#IMS26 #mmsm Plenary Long term follow up PERSEUS ➡️Median follow up ~7 years Dara-RVD showed better PFS of 81% vs. 56% with better MRD negativity at both 10-5 and 10-6 sensitivity thresholds (lower numbers with high risk disease) ➡️~ 3 out of 4 DVRd-DR patients receiving maintenance achieved 12-month sustained MRD negativity, with subsequent discontinuation of daratumumab OS still not statistically different Amazing long therapy results with Quad induction, transplant and maintenance therapy

Post attachmentPost attachmentPost attachmentPost attachment
Myeloma Society avatar
⟳ Tracy King retweeted
Myeloma Society@Myeloma_Society·Sep 24

We should prioritize quality of life (QoL) as an endpoint in MM clinical trials, especially in high-risk patients --- Karthik Ramasamy, MD, PhD. He presented QoL data from the RADAR trial in newly diagnosed pts w/ ultra high-risk MM. #IMS26

Post attachment
Tracy King avatar
Tracy King@MMKingT·Sep 23

Nice work from @DrRakeshPopat and UK Myeloma Society ProMMise D trial testing use of PROM tool VRAT to assess ocular toxicity in #BelMaf and potential to avoid formal ocular exams.

Post attachment